Uveitis, Intermediate clinical trials
The registry lists 56 studies for Uveitis, Intermediate across more than 10 countries. 2 are recruiting or about to start. 9 of them are mainly about Uveitis, Intermediate (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-05. Counting its narrower condition Pars Planitis too: 57 studies, 2 open.
Get an email when these change. Save the Uveitis, Intermediate studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Eye Institute (NEI) (8) · Novartis Pharmaceuticals (6) · Clearside Biomedical, Inc. (5) · XOMA (US) LLC (3) · Targeted Therapy Technologies, LLC (2) · Johns Hopkins University (2) · EyePoint Pharmaceuticals, Inc. (2) · Lux Biosciences, Inc. (2)
What is being tested here
Drugs under test in Uveitis, Intermediate studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Drug classes tested here Corticosteroids 7
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Who these studies take
Of the 1 Uveitis, Intermediate studies recruiting now, 1 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (100%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 1 (100%) | 1 (100%) |
| 30 | 1 (100%) | 1 (100%) |
| 40 | 1 (100%) | 1 (100%) |
| 50 | 1 (100%) | 1 (100%) |
| 65 | 1 (100%) | 1 (100%) |
| 75 | 1 (100%) | 1 (100%) |
| 85 | 1 (100%) | 1 (100%) |
Across all 56 studies, recruiting or not: 7% stop at 75 or younger and 0% at 65; 18% take children; 0% are for women only and 0% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 56. Browse all 56 → or search them.
- Adalimumab Dose Adjustment for Pediatric Uveitis Treatment TrialNot yet recruitingNCT07699107Phase 43 countries
- Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept StudyRecruitingNCT06085079Phase 41 country
- The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior SegmentCompletedNCT05486468Phase 31 country
- A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior UveitisActive, not recruitingNCT06431373Phase 313 countries
- ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study)CompletedNCT02931175Phase 21 country
- Adalimumab in JIA-associated Uveitis Stopping TrialCompletedNCT03816397Phase 43 countries
- Ozurdex Monotherapy TrialWithdrawnNCT05101928Phase 41 country
- Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitisTerminatedNCT05384249Phase 27 countries
- Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) InsertTerminatedNCT05070728Phase 31 country
- The Vitreous Proteome and Inflammatory Mediators in Ocular Inflammatory DiseaseCompletedNCT003313311 country
- POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIUTerminatedNCT05953688Phase 21 country
- A Phase I/IIa Study for the Treatment of Uveitis With IontophoresisWithdrawnNCT00499551Phase 1/21 country
- Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior PoleActive, not recruitingNCT04120636Phase 11 country
- Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior PoleActive, not recruitingNCT04120311Phase 11 country
- Intravitreal Sirolimus as Therapeutic Approach to UveitisWithdrawnNCT01280669Phase 21 country
- Human Samples and Data RepositoryTerminatedNCT005393701 country
- Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)TerminatedNCT03656692Phase 41 country
- A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitisCompletedNCT01148225Phase 3
- Suprachoroidal Injection of CLS-TA in Patients With Non-infectious UveitisCompletedNCT03097315Phase 31 country
- MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301CompletedNCT029520012 countries
- Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious UveitisCompletedNCT02595398Phase 33 countries
- Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)CompletedNCT02911116Phase 21 country
- Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat UveitisCompletedNCT01789320Phase 1/21 country
- Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious UveitisCompletedNCT02255032Phase 21 country
- Variations in Retinal Nerve Fiber Layer Thickness During Uncomplicated Anterior and Intermediate UveitisCompletedNCT028790841 country
- Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious UveitisWithdrawnNCT01103024Phase 35 countries
- Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior UveitisCompletedNCT02746991Phase 31 country
- Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X)TerminatedNCT02375685Phase 313 countries
- Immunogenetic Mechanisms in Behcet's DiseaseTerminatedNCT011094331 country
- Pilot Project: The Amplicon and Metatranscriptomic Study of Intra and Extra Intestinal Microbiome in Non-infectious Uveitis DiseaseStatus unknownNCT041268501 country
- Study of the Effectiveness of Ozurdex for the Control of UveitisCompletedNCT02049476Phase 41 country
- Sirolimus as Therapeutic Approach to UveitisCompletedNCT00908466Phase 11 country
- Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis PatientsCompletedNCT02764697Phase 41 country
- Safety &Efficacy of CF101 to Subjects With UveitisWithdrawnNCT01905124Phase 21 country
- Safety and Efficacy of AIN457 in Noninfectious UveitisCompletedNCT00685399Phase 22 countries
- The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon GammaCompletedNCT00943982Phase 11 country
- Myfortic for the Treatment of Non-infectious Intermediate UveitisCompletedNCT01092533Phase 31 country
- Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS StudyStatus unknownNCT01717170Phase 1/21 country
- Safety and Preliminary Efficacy Study of V404 PDS in UveitisTerminatedNCT02125266Phase 1/21 country
- Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic TreatmentTerminatedNCT01747538Phase 322 countries
- Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious UveitisTerminatedNCT01684345Phase 322 countries
- Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious UveitisTerminatedNCT01090310Phase 38 countries
- Assessment of Retinal Nerve Fibre Layer by Optical Coherence Tomography in Uveitis Patients With PapilloedemaCompletedNCT011704811 country
- Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious UveitisTerminatedNCT01032915Phase 310 countries
- Safety and Efficacy of AIN457 in Patients With Active Non-infectious UveitisTerminatedNCT01095250Phase 313 countries
- An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety DataTerminatedNCT02258854Phase 31 country
- Phase III Study in Refractory Behcet's DiseaseCompletedNCT00995709Phase 317 countries
- Retisert and Cataract Surgery in Patients With Severe UveitisCompletedNCT00570830Not applicable1 country
- Study to Evaluate the Long Term Use of Treatment With AIN457 for UveitisWithdrawnNCT01327664Phase 3
- Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate UveitisCompletedNCT00344253Phase 31 country